Inhibitory receptor CD47 binding to plasma TSP1 suppresses NK-cell IFN-γ production via activating the JAK/STAT3 pathway during HIV infection

Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodefici...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 21; no. 1; pp. 869 - 13
Main Authors Lang, Bin, Wang, Meiting, Zhang, Zining, Fu, Yajing, Han, Xiaoxu, Hu, Qinghai, Ding, Haibo, Shang, Hong, Jiang, Yongjun
Format Journal Article
LanguageEnglish
Published England BioMed Central 30.11.2023
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodeficiency virus (HIV) infection remain unclear. Fresh peripheral blood mononuclear cells (PBMCs) were collected from people living with HIV (PLWH) and HIV negative controls (NC) subjects. Soluble ligand expression levels of CD47 were measured using ELISA. HIV viral proteins or Toll-like receptor 7/8 (TLR7/8) agonist was used to investigate the mechanisms underlying the upregulation of CD47 expression. The effect of CD47 on NK cell activation, proliferation, and function were evaluated by flow cytometry. RNA-seq was used to identify downstream pathways for CD47 and its ligand interactions. A small molecule inhibitor was used to restore the inhibition of NK cell function by CD47 signalling. CD47 expression was highly upregulated on the NK cells from PLWH, which could be due to activation of the Toll-like receptor 7/8 (TLR7/8) pathway. Compared with NC subjects, PLWH subjects exhibited elevated levels of CD47 ligands, thrombospondin-1 (TSP1), and counter ligand signal regulatory protein-α (SIRPα). The TSP1-CD47 axis drives the suppression of interferon gamma (IFN-γ) production and the activation of the Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway in NK cells. After treatment with a STAT3 inhibitor, the NK cells from PLWH showed significantly improved IFN-γ production. The current data indicate that the binding of the inhibitory receptor CD47 to plasma TSP1 suppresses NK cell IFN-γ production by activating the JAK/STAT3 pathway during HIV infection. Our results suggest that CD47 and its related signalling pathways could be targets for improving NK cell function in people living with HIV.
AbstractList Abstract Background Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodeficiency virus (HIV) infection remain unclear. Methods Fresh peripheral blood mononuclear cells (PBMCs) were collected from people living with HIV (PLWH) and HIV negative controls (NC) subjects. Soluble ligand expression levels of CD47 were measured using ELISA. HIV viral proteins or Toll-like receptor 7/8 (TLR7/8) agonist was used to investigate the mechanisms underlying the upregulation of CD47 expression. The effect of CD47 on NK cell activation, proliferation, and function were evaluated by flow cytometry. RNA-seq was used to identify downstream pathways for CD47 and its ligand interactions. A small molecule inhibitor was used to restore the inhibition of NK cell function by CD47 signalling. Results CD47 expression was highly upregulated on the NK cells from PLWH, which could be due to activation of the Toll-like receptor 7/8 (TLR7/8) pathway. Compared with NC subjects, PLWH subjects exhibited elevated levels of CD47 ligands, thrombospondin-1 (TSP1), and counter ligand signal regulatory protein-α (SIRPα). The TSP1–CD47 axis drives the suppression of interferon gamma (IFN-γ) production and the activation of the Janus kinase signal transducer and activator of transcription (JAK–STAT) pathway in NK cells. After treatment with a STAT3 inhibitor, the NK cells from PLWH showed significantly improved IFN-γ production. Conclusions The current data indicate that the binding of the inhibitory receptor CD47 to plasma TSP1 suppresses NK cell IFN-γ production by activating the JAK/STAT3 pathway during HIV infection. Our results suggest that CD47 and its related signalling pathways could be targets for improving NK cell function in people living with HIV.
Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodeficiency virus (HIV) infection remain unclear.BACKGROUNDNatural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodeficiency virus (HIV) infection remain unclear.Fresh peripheral blood mononuclear cells (PBMCs) were collected from people living with HIV (PLWH) and HIV negative controls (NC) subjects. Soluble ligand expression levels of CD47 were measured using ELISA. HIV viral proteins or Toll-like receptor 7/8 (TLR7/8) agonist was used to investigate the mechanisms underlying the upregulation of CD47 expression. The effect of CD47 on NK cell activation, proliferation, and function were evaluated by flow cytometry. RNA-seq was used to identify downstream pathways for CD47 and its ligand interactions. A small molecule inhibitor was used to restore the inhibition of NK cell function by CD47 signalling.METHODSFresh peripheral blood mononuclear cells (PBMCs) were collected from people living with HIV (PLWH) and HIV negative controls (NC) subjects. Soluble ligand expression levels of CD47 were measured using ELISA. HIV viral proteins or Toll-like receptor 7/8 (TLR7/8) agonist was used to investigate the mechanisms underlying the upregulation of CD47 expression. The effect of CD47 on NK cell activation, proliferation, and function were evaluated by flow cytometry. RNA-seq was used to identify downstream pathways for CD47 and its ligand interactions. A small molecule inhibitor was used to restore the inhibition of NK cell function by CD47 signalling.CD47 expression was highly upregulated on the NK cells from PLWH, which could be due to activation of the Toll-like receptor 7/8 (TLR7/8) pathway. Compared with NC subjects, PLWH subjects exhibited elevated levels of CD47 ligands, thrombospondin-1 (TSP1), and counter ligand signal regulatory protein-α (SIRPα). The TSP1-CD47 axis drives the suppression of interferon gamma (IFN-γ) production and the activation of the Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway in NK cells. After treatment with a STAT3 inhibitor, the NK cells from PLWH showed significantly improved IFN-γ production.RESULTSCD47 expression was highly upregulated on the NK cells from PLWH, which could be due to activation of the Toll-like receptor 7/8 (TLR7/8) pathway. Compared with NC subjects, PLWH subjects exhibited elevated levels of CD47 ligands, thrombospondin-1 (TSP1), and counter ligand signal regulatory protein-α (SIRPα). The TSP1-CD47 axis drives the suppression of interferon gamma (IFN-γ) production and the activation of the Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway in NK cells. After treatment with a STAT3 inhibitor, the NK cells from PLWH showed significantly improved IFN-γ production.The current data indicate that the binding of the inhibitory receptor CD47 to plasma TSP1 suppresses NK cell IFN-γ production by activating the JAK/STAT3 pathway during HIV infection. Our results suggest that CD47 and its related signalling pathways could be targets for improving NK cell function in people living with HIV.CONCLUSIONSThe current data indicate that the binding of the inhibitory receptor CD47 to plasma TSP1 suppresses NK cell IFN-γ production by activating the JAK/STAT3 pathway during HIV infection. Our results suggest that CD47 and its related signalling pathways could be targets for improving NK cell function in people living with HIV.
Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodeficiency virus (HIV) infection remain unclear. Fresh peripheral blood mononuclear cells (PBMCs) were collected from people living with HIV (PLWH) and HIV negative controls (NC) subjects. Soluble ligand expression levels of CD47 were measured using ELISA. HIV viral proteins or Toll-like receptor 7/8 (TLR7/8) agonist was used to investigate the mechanisms underlying the upregulation of CD47 expression. The effect of CD47 on NK cell activation, proliferation, and function were evaluated by flow cytometry. RNA-seq was used to identify downstream pathways for CD47 and its ligand interactions. A small molecule inhibitor was used to restore the inhibition of NK cell function by CD47 signalling. CD47 expression was highly upregulated on the NK cells from PLWH, which could be due to activation of the Toll-like receptor 7/8 (TLR7/8) pathway. Compared with NC subjects, PLWH subjects exhibited elevated levels of CD47 ligands, thrombospondin-1 (TSP1), and counter ligand signal regulatory protein-α (SIRPα). The TSP1-CD47 axis drives the suppression of interferon gamma (IFN-γ) production and the activation of the Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway in NK cells. After treatment with a STAT3 inhibitor, the NK cells from PLWH showed significantly improved IFN-γ production. The current data indicate that the binding of the inhibitory receptor CD47 to plasma TSP1 suppresses NK cell IFN-γ production by activating the JAK/STAT3 pathway during HIV infection. Our results suggest that CD47 and its related signalling pathways could be targets for improving NK cell function in people living with HIV.
BackgroundNatural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among these inhibitory receptors, the expression, function, and mechanism of cluster of differentiation 47 (CD47) on NK cells during human immunodeficiency virus (HIV) infection remain unclear.MethodsFresh peripheral blood mononuclear cells (PBMCs) were collected from people living with HIV (PLWH) and HIV negative controls (NC) subjects. Soluble ligand expression levels of CD47 were measured using ELISA. HIV viral proteins or Toll-like receptor 7/8 (TLR7/8) agonist was used to investigate the mechanisms underlying the upregulation of CD47 expression. The effect of CD47 on NK cell activation, proliferation, and function were evaluated by flow cytometry. RNA-seq was used to identify downstream pathways for CD47 and its ligand interactions. A small molecule inhibitor was used to restore the inhibition of NK cell function by CD47 signalling.ResultsCD47 expression was highly upregulated on the NK cells from PLWH, which could be due to activation of the Toll-like receptor 7/8 (TLR7/8) pathway. Compared with NC subjects, PLWH subjects exhibited elevated levels of CD47 ligands, thrombospondin-1 (TSP1), and counter ligand signal regulatory protein-α (SIRPα). The TSP1–CD47 axis drives the suppression of interferon gamma (IFN-γ) production and the activation of the Janus kinase signal transducer and activator of transcription (JAK–STAT) pathway in NK cells. After treatment with a STAT3 inhibitor, the NK cells from PLWH showed significantly improved IFN-γ production.ConclusionsThe current data indicate that the binding of the inhibitory receptor CD47 to plasma TSP1 suppresses NK cell IFN-γ production by activating the JAK/STAT3 pathway during HIV infection. Our results suggest that CD47 and its related signalling pathways could be targets for improving NK cell function in people living with HIV.
ArticleNumber 869
Author Wang, Meiting
Hu, Qinghai
Jiang, Yongjun
Zhang, Zining
Lang, Bin
Ding, Haibo
Fu, Yajing
Han, Xiaoxu
Shang, Hong
Author_xml – sequence: 1
  givenname: Bin
  surname: Lang
  fullname: Lang, Bin
– sequence: 2
  givenname: Meiting
  surname: Wang
  fullname: Wang, Meiting
– sequence: 3
  givenname: Zining
  surname: Zhang
  fullname: Zhang, Zining
– sequence: 4
  givenname: Yajing
  surname: Fu
  fullname: Fu, Yajing
– sequence: 5
  givenname: Xiaoxu
  surname: Han
  fullname: Han, Xiaoxu
– sequence: 6
  givenname: Qinghai
  surname: Hu
  fullname: Hu, Qinghai
– sequence: 7
  givenname: Haibo
  surname: Ding
  fullname: Ding, Haibo
– sequence: 8
  givenname: Hong
  orcidid: 0000-0002-8907-8124
  surname: Shang
  fullname: Shang, Hong
– sequence: 9
  givenname: Yongjun
  surname: Jiang
  fullname: Jiang, Yongjun
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38037074$$D View this record in MEDLINE/PubMed
BookMark eNp9ks9u1DAQxiNURP_AC3BAlrhwCbUd27FPqFooXVoVpC5crYnj7HqVjVM7WbQvwcvwHjwT3t1StT1wmk-eb34az8xxdtD5zmbZa4LfEyLFaSRUiTLHtMgxE0mJZ9kRYaXKuSzFwQN9mB3HuMSYMs7Ui-ywkLgoccmOsl_TbuEqN_iwQcEa2yeFJh9ZiSrX1a6bo8GjvoW4AjS7-UZQHPs-2BhtRNeXubFti6bn1_mf36gPvh7N4HyH1g4QJLmGYYdYWPTl7PL0ZnY2K1APw-InbFA9hm3yYvoDua6xu8qX2fMG2mhf3cWT7Pv5p9nkIr_6-nk6ObvKDVPlkBcKSqAVL6qkGKdEGFlbDrW1zMoKamAlVJyrqgTTGMPLihtay1owSnglipNsuufWHpa6D24FYaM9OL178GGuIQzOtFZbqQqhGsKwMIwQooxKUTYNNdwWGBLrw57Vj9XK1sZ2Q4D2EfRxpnMLPfdrTbCQEqsiEd7dEYK_HW0c9MrF7Wihs36MmkolJKaS8GR9-8S69GPo0qw0VZiSQnK-Bb552NJ9L__2ngx0bzDBxxhsc28hWG-PS--PS6fj0rvj0tuhySdFxg2wXVv6lmv_V_oXbhPUog
CitedBy_id crossref_primary_10_1016_j_apsb_2024_11_018
crossref_primary_10_1002_mc_23855
crossref_primary_10_3390_v17030309
Cites_doi 10.1084/jem.20200839
10.1146/annurev.iy.02.040184.002143
10.1128/JVI.77.4.2663-2674.2003
10.3390/cancers6020926
10.1016/j.canlet.2021.09.028
10.1128/jvi.65.11.6277-6282.1991
10.1016/j.ejca.2022.02.009
10.3390/cancers13246229
10.1016/j.it.2017.12.005
10.1038/s41541-022-00477-x
10.1182/blood-2007-08-105965
10.3389/fmicb.2023.1033448
10.1200/JCO.19.00121
10.1146/annurev-immunol-032712-100001
10.1016/0161-5890(94)90092-2
10.1038/s41590-021-00943-z
10.1158/2159-8290.CD-21-0407
10.1016/j.cell.2020.01.022
10.3389/fimmu.2021.792775
10.1189/jlb.69.6.912
10.1158/0008-5472.CAN-20-2426
10.1158/2326-6066.CIR-18-0367
10.4049/jimmunol.177.6.3534
10.1159/000132568
10.1053/j.seminoncol.2020.05.009
10.1097/01.cji.0000211327.76266.65
10.1001/jama.2016.4059
10.1073/pnas.0507484102
10.1128/mBio.01293-20
10.1016/j.yexcr.2015.07.007
10.1056/NEJMoa1305133
10.1111/imr.12524
10.1016/j.immuni.2016.05.001
10.1074/jbc.M110.179663
10.3389/fimmu.2018.00474
10.3390/biom13050748
10.1038/s41586-018-0600-6
10.1038/s41467-022-31196-5
10.1186/s12865-021-00417-9
10.1038/ncomms14802
10.1111/imr.12519
10.1016/j.immuni.2020.04.011
10.1155/2015/178698
10.1182/blood-2014-03-564450
10.1242/jcs.108.11.3419
10.1126/sciimmunol.abb1025
10.4049/jimmunol.1900856
10.1128/jvi.67.5.2844-2852.1993
ContentType Journal Article
Copyright 2023. The Author(s).
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s12967-023-04667-6
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 13
ExternalDocumentID oai_doaj_org_article_e89369f1406c41119c9c418ff2c5e30a
PMC10688093
38037074
10_1186_s12967_023_04667_6
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: the China 13th Five-Year Plan of National Science Research
  grantid: 2017ZX10201101
– fundername: Scientific Research Project of Higher Education in Liaoning province
  grantid: LJKZ0737
– fundername: The National Key Research and Development Program of China
  grantid: 2021YFC2301802
– fundername: Science and Technology Innovation Team of China Medical University
  grantid: CXTD2022003
– fundername: ;
  grantid: LJKZ0737
– fundername: ;
  grantid: CXTD2022003
– fundername: ;
  grantid: 2017ZX10201101
– fundername: ;
  grantid: 2021YFC2301802
GroupedDBID ---
0R~
29L
2WC
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c497t-39a7a2b53b39a45216c8de5adee4e8bada47ab559b7acfcc57b5c2d8d64215b63
IEDL.DBID M48
ISSN 1479-5876
IngestDate Wed Aug 27 00:58:29 EDT 2025
Thu Aug 21 18:35:49 EDT 2025
Fri Jul 11 10:27:33 EDT 2025
Sat Jul 26 00:12:47 EDT 2025
Thu Jan 02 22:27:17 EST 2025
Tue Jul 01 02:59:42 EDT 2025
Thu Apr 24 23:10:22 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords JAK–STAT3
IFN-γ
NK cells
CD47
HIV infection
TSP1
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c497t-39a7a2b53b39a45216c8de5adee4e8bada47ab559b7acfcc57b5c2d8d64215b63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-8907-8124
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12967-023-04667-6
PMID 38037074
PQID 2902138553
PQPubID 43076
PageCount 13
ParticipantIDs doaj_primary_oai_doaj_org_article_e89369f1406c41119c9c418ff2c5e30a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10688093
proquest_miscellaneous_2896802815
proquest_journals_2902138553
pubmed_primary_38037074
crossref_primary_10_1186_s12967_023_04667_6
crossref_citationtrail_10_1186_s12967_023_04667_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-11-30
PublicationDateYYYYMMDD 2023-11-30
PublicationDate_xml – month: 11
  year: 2023
  text: 2023-11-30
  day: 30
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of translational medicine
PublicationTitleAlternate J Transl Med
PublicationYear 2023
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References 4667_CR20
4667_CR41
4667_CR26
L Ni (4667_CR2) 2017; 276
P Betancur (4667_CR31) 2017; 8
D Gotthardt (4667_CR48) 2014; 124
O Hamid (4667_CR9) 2013; 369
P Nath (4667_CR24) 2019; 7
N Oyaizu (4667_CR29) 1991; 65
A Ribas (4667_CR10) 2016; 315
C Carlino (4667_CR40) 2008; 111
N Dizman (4667_CR14) 2021; 13
M Reinhold (4667_CR11) 1995; 108
M Kortylewski (4667_CR46) 2007; 30
S Kaur (4667_CR17) 2011; 286
N Jacquelot (4667_CR4) 2021; 22
M Kim (4667_CR25) 2008; 29
C Fionda (4667_CR47) 2015; 2015
L Andrews (4667_CR3) 2017; 276
S Rinaldi (4667_CR28) 2020; 204
E Borducchi (4667_CR38) 2018; 563
D Peppa (4667_CR23) 2018; 9
S Jost (4667_CR22) 2013; 31
A Anderson (4667_CR1) 2016; 44
J Ventura (4667_CR36) 2022; 7
Y Chen (4667_CR33) 1994; 31
B Oronsky (4667_CR15) 2020; 47
P Grimbert (4667_CR18) 2006; 177
A Veillette (4667_CR13) 2018; 39
4667_CR35
A Veillette (4667_CR16) 2019; 37
U Wille-Reece (4667_CR43) 2005; 102
M de Veer (4667_CR32) 2001; 69
V Walker-Sperling (4667_CR39) 2022; 13
X Yu (4667_CR21) 2021; 22
P Adusumilli (4667_CR7) 2021; 11
M Tal (4667_CR19) 2020; 11
M Logtenberg (4667_CR12) 2020; 52
Y Li (4667_CR37) 2023; 14
P Xu (4667_CR45) 2015; 337
A Xiong (4667_CR44) 2014; 6
E Unanue (4667_CR27) 1984; 2
W Shi (4667_CR6) 2021; 522
Y Adachi (4667_CR5) 2022; 82
C Jassoy (4667_CR30) 1993; 67
U Malhotra (4667_CR34) 2003; 77
P Dogra (4667_CR42) 2020; 180
M Kudo (4667_CR8) 2022; 167
References_xml – ident: 4667_CR20
  doi: 10.1084/jem.20200839
– volume: 2
  start-page: 395
  year: 1984
  ident: 4667_CR27
  publication-title: Annual Rev Immunol.
  doi: 10.1146/annurev.iy.02.040184.002143
– volume: 77
  start-page: 2663
  issue: 4
  year: 2003
  ident: 4667_CR34
  publication-title: J Virol.
  doi: 10.1128/JVI.77.4.2663-2674.2003
– volume: 6
  start-page: 926
  issue: 2
  year: 2014
  ident: 4667_CR44
  publication-title: Cancers.
  doi: 10.3390/cancers6020926
– volume: 522
  start-page: 184
  year: 2021
  ident: 4667_CR6
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2021.09.028
– volume: 65
  start-page: 6277
  issue: 11
  year: 1991
  ident: 4667_CR29
  publication-title: J Virol
  doi: 10.1128/jvi.65.11.6277-6282.1991
– volume: 167
  start-page: 1
  year: 2022
  ident: 4667_CR8
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2022.02.009
– volume: 13
  start-page: 6229
  issue: 24
  year: 2021
  ident: 4667_CR14
  publication-title: Cancers
  doi: 10.3390/cancers13246229
– volume: 39
  start-page: 173
  issue: 3
  year: 2018
  ident: 4667_CR13
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2017.12.005
– volume: 7
  start-page: 53
  issue: 1
  year: 2022
  ident: 4667_CR36
  publication-title: NPJ Vaccines.
  doi: 10.1038/s41541-022-00477-x
– volume: 111
  start-page: 3108
  issue: 6
  year: 2008
  ident: 4667_CR40
  publication-title: Blood.
  doi: 10.1182/blood-2007-08-105965
– volume: 14
  start-page: 1033448
  year: 2023
  ident: 4667_CR37
  publication-title: Front Microbiol.
  doi: 10.3389/fmicb.2023.1033448
– volume: 37
  start-page: 1012
  issue: 12
  year: 2019
  ident: 4667_CR16
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.00121
– volume: 31
  start-page: 163
  year: 2013
  ident: 4667_CR22
  publication-title: Annu Rev Immunol.
  doi: 10.1146/annurev-immunol-032712-100001
– volume: 31
  start-page: 977
  issue: 13
  year: 1994
  ident: 4667_CR33
  publication-title: Mol Immunol.
  doi: 10.1016/0161-5890(94)90092-2
– volume: 22
  start-page: 851
  issue: 7
  year: 2021
  ident: 4667_CR4
  publication-title: Nat Immunol
  doi: 10.1038/s41590-021-00943-z
– volume: 11
  start-page: 2748
  issue: 11
  year: 2021
  ident: 4667_CR7
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-21-0407
– volume: 180
  start-page: 749
  issue: 4
  year: 2020
  ident: 4667_CR42
  publication-title: Cell.
  doi: 10.1016/j.cell.2020.01.022
– ident: 4667_CR26
  doi: 10.3389/fimmu.2021.792775
– volume: 69
  start-page: 912
  issue: 6
  year: 2001
  ident: 4667_CR32
  publication-title: J Leukoc Biol.
  doi: 10.1189/jlb.69.6.912
– volume: 82
  start-page: 292
  issue: 2
  year: 2022
  ident: 4667_CR5
  publication-title: Can Res
  doi: 10.1158/0008-5472.CAN-20-2426
– volume: 7
  start-page: 1547
  issue: 9
  year: 2019
  ident: 4667_CR24
  publication-title: Cancer Immunol Res.
  doi: 10.1158/2326-6066.CIR-18-0367
– volume: 177
  start-page: 3534
  issue: 6
  year: 2006
  ident: 4667_CR18
  publication-title: J Immunol
  doi: 10.4049/jimmunol.177.6.3534
– volume: 29
  start-page: 28
  issue: 1
  year: 2008
  ident: 4667_CR25
  publication-title: Tumour Biol.
  doi: 10.1159/000132568
– volume: 47
  start-page: 117
  year: 2020
  ident: 4667_CR15
  publication-title: Semin Oncol
  doi: 10.1053/j.seminoncol.2020.05.009
– volume: 30
  start-page: 131
  issue: 2
  year: 2007
  ident: 4667_CR46
  publication-title: J Immunother.
  doi: 10.1097/01.cji.0000211327.76266.65
– volume: 315
  start-page: 1600
  issue: 15
  year: 2016
  ident: 4667_CR10
  publication-title: JAMA
  doi: 10.1001/jama.2016.4059
– volume: 102
  start-page: 15190
  issue: 42
  year: 2005
  ident: 4667_CR43
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0507484102
– volume: 11
  start-page: 10
  issue: 3
  year: 2020
  ident: 4667_CR19
  publication-title: MBio.
  doi: 10.1128/mBio.01293-20
– volume: 337
  start-page: 53
  issue: 1
  year: 2015
  ident: 4667_CR45
  publication-title: Exp Cell Res.
  doi: 10.1016/j.yexcr.2015.07.007
– volume: 369
  start-page: 134
  issue: 2
  year: 2013
  ident: 4667_CR9
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1305133
– volume: 276
  start-page: 52
  issue: 1
  year: 2017
  ident: 4667_CR2
  publication-title: Immunol Rev
  doi: 10.1111/imr.12524
– volume: 44
  start-page: 989
  issue: 5
  year: 2016
  ident: 4667_CR1
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.05.001
– volume: 286
  start-page: 14991
  issue: 17
  year: 2011
  ident: 4667_CR17
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M110.179663
– volume: 9
  start-page: 474
  year: 2018
  ident: 4667_CR23
  publication-title: Front Immunol.
  doi: 10.3389/fimmu.2018.00474
– ident: 4667_CR41
  doi: 10.3390/biom13050748
– volume: 563
  start-page: 360
  issue: 7731
  year: 2018
  ident: 4667_CR38
  publication-title: Nature.
  doi: 10.1038/s41586-018-0600-6
– volume: 13
  start-page: 3463
  issue: 1
  year: 2022
  ident: 4667_CR39
  publication-title: Nat Commun.
  doi: 10.1038/s41467-022-31196-5
– volume: 22
  start-page: 25
  issue: 1
  year: 2021
  ident: 4667_CR21
  publication-title: BMC Immunol.
  doi: 10.1186/s12865-021-00417-9
– volume: 8
  start-page: 14802
  year: 2017
  ident: 4667_CR31
  publication-title: Nat Commun.
  doi: 10.1038/ncomms14802
– volume: 276
  start-page: 80
  issue: 1
  year: 2017
  ident: 4667_CR3
  publication-title: Immunol Rev
  doi: 10.1111/imr.12519
– volume: 52
  start-page: 742
  issue: 5
  year: 2020
  ident: 4667_CR12
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.04.011
– volume: 2015
  start-page: 178698
  year: 2015
  ident: 4667_CR47
  publication-title: Biomed Res Int
  doi: 10.1155/2015/178698
– volume: 124
  start-page: 2370
  issue: 15
  year: 2014
  ident: 4667_CR48
  publication-title: Blood.
  doi: 10.1182/blood-2014-03-564450
– volume: 108
  start-page: 3419
  year: 1995
  ident: 4667_CR11
  publication-title: J Cell Sci
  doi: 10.1242/jcs.108.11.3419
– ident: 4667_CR35
  doi: 10.1126/sciimmunol.abb1025
– volume: 204
  start-page: 540
  issue: 3
  year: 2020
  ident: 4667_CR28
  publication-title: J Immunol (Baltimore, Md: 1950)
  doi: 10.4049/jimmunol.1900856
– volume: 67
  start-page: 2844
  issue: 5
  year: 1993
  ident: 4667_CR30
  publication-title: J Virol.
  doi: 10.1128/jvi.67.5.2844-2852.1993
SSID ssj0024549
Score 2.410172
Snippet Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression. Among...
BackgroundNatural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor expression....
Abstract Background Natural killer (NK) cells play an important first-line role against tumour and viral infections and are regulated by inhibitory receptor...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 869
SubjectTerms Antibodies
CD47
CD47 Antigen
Cell activation
Cell differentiation
Enzyme-linked immunosorbent assay
Flow cytometry
HIV
HIV infection
HIV Infections
Human immunodeficiency virus
Humans
IFN-γ
Infections
Interferon-gamma - metabolism
JAK–STAT3
Janus kinase
Janus Kinases - metabolism
Killer Cells, Natural - metabolism
Leukocytes (mononuclear)
Leukocytes, Mononuclear - metabolism
Ligands
Lymphocytes
Natural killer cells
NK cells
Peripheral blood mononuclear cells
Phosphorylation
Plasma
Proteins
Receptor mechanisms
Signal regulatory protein-α
Signal transduction
Software
Stat3 protein
STAT3 Transcription Factor - metabolism
Thrombospondin
TLR7 protein
Toll-Like Receptor 7
Toll-like receptors
TSP1
γ-Interferon
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtMwELbQHlZcECx_gQUNEjcUNYl_4hzL7lbtrrZC2i7am2U7jhppSSPagngJXob34JkYO0m1RQgunGo1TuVmZjzfODPfEPLWaVEhUE7j1FIMUDJnY60rFldWJlpnunTOn0NezsX0mp3f8Js7rb58TlhHD9w9uJGTvuVchXGAsAwNs7AFfsqqyix3NAnQCH3eEEwNLHsY9gwlMlKM1ujVcENA_-RTGXEk9txQYOv_E8T8PVPyjuuZPCQPeswI426tj8g91xyRw8v-rfhj8n3WLGtT-9flgBuYa3EEJ6csB1OHohXYrKBFmPxJw-LqQwrrbRvyX90a5hexP7uH2WQe__wBbUcAi8KCL7UGX_Xgz2z9TywdnI8vRleL8YKCb2T8VX-DrsoRprOPMKR1NU_I9eRscTKN-z4LsWVFvolpoXOdGU4Njhj6c2Fl6XiQk5NGl5rl2mDoYXJtK2t5brjNSln6IlluBH1KDppV454TQPSH8RRCNgSCuBsUUugqYTlliWWl5iIi6fDYle1JyH0vjFsVghEpVCcqhaJSQVQK73m3u6ftKDj-Ovu9l-ZupqfPDl-gUqleqdS_lCoix4MuqN6m1yorEA9RyTmNyJvdZbRGLybduNUW58hCSIRsKY_Is051diuhMqE5IraIyD2l2lvq_pWmXgbG79S3BkoK-uJ__LmX5H7mLSHwVx6Tg83nrXuFyGpjXgcj-gVfKR_B
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NjtMwELZgkRAXxD-BBRmJG4qaxD9xTqgsVO2utkLaLurNchxnGwmSsG1BvAQvw3vwTMw4SZcitKdYiRNZmfHMN-P5IeS1M7IEoByHsWVgoCTOhsaUPCytioxJTOEc-iFP53J6zo-XYtk73NZ9WOUgE72gLhqLPvJRkoE2YkoI9rb9GmLXKDxd7Vto3CS3sHQZcnW6vDK4OBg_Q6KMkqM16DYQC6ClMKARRnJPGfma_f8Dmv_GS_6lgCb3yN0eOdJxR-r75IarH5Dbp_3Z-EPyc1avqrzCQ3MKYsy1MKJH73lK88qnrtBNQ1sAy18MXZx9jOl62_ooWLem85MQPfh0NpmHv3_RtisDCySj3ypDMfcBPbf4iZWjx-OT0dlivGAU2xl_Nz9ol-tIp7NPdAjuqh-R88mHxdE07LsthJZn6SZkmUlNkguWw4iDVpdWFU54ajmVm8Lw1ORggOSpsaW1Is2FTQpVYKqsyCV7TA7qpnZPCQUMCFYVADeAgyATMiVNGfGU8cjywggZkHj47dr2pcixI8Zn7U0SJXVHKg2k0p5UGt55s3un7QpxXDv7HVJzNxOLaPsbzeWF7vekdgq7GZZgYkrLQeZnNoOrKsvECsciE5DDgRd0v7PX-ooPA_Jq9xj2JJLJ1K7ZwhyVSQXALRYBedKxzm4lTEUsBdwWELXHVHtL3X9SVytf9zvGBkFRxp5dv67n5E6CPO7rUx6Sg83l1r0A5LTJX_rt8Qcx2Bfb
  priority: 102
  providerName: ProQuest
Title Inhibitory receptor CD47 binding to plasma TSP1 suppresses NK-cell IFN-γ production via activating the JAK/STAT3 pathway during HIV infection
URI https://www.ncbi.nlm.nih.gov/pubmed/38037074
https://www.proquest.com/docview/2902138553
https://www.proquest.com/docview/2896802815
https://pubmed.ncbi.nlm.nih.gov/PMC10688093
https://doaj.org/article/e89369f1406c41119c9c418ff2c5e30a
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELb2ISEuiDeBpTISNxQ2iZ85INQuW7W7arXabVHFJXIch0Za0tIHsH-CP8P_4DcxdpJCUcWJS2LFduR4PJlvxp4ZhF4axXMAyqEfagIKSmS0r1RO_VzLQKlIZcZYO-RgyHtjejZhkz3UpDuqJ3C5U7Wz-aTGi-vX3z7fvAWGf-MYXvLjJcgsYHeQPvagIpT4PjoEySRsRoMBlb9j74Ey1DjO7Oy3JZxcDP9dwPPv85N_CKTuXXSnRpK4XZH-Htoz5X10a1DvlT9A3_vltEgLu4mO4bdm5lDCJ--owGnhXFnwaobnAJ4_KTy6ugjxcj13p2LNEg_PfWvRx_3u0P_5A8-rsLBAQvylUNj6QlhLrn3F1OCz9vnx1ag9ItimN_6qbnDl-4h7_fe4OexVPkTj7unopOfX2Rd8TWOx8kmshIpSRlIoUZDyXMvMMEc9I1OVKSpUCgpJKpTOtWYiZTrKZGZdZ1nKySN0UM5K8wRhwISgZQGQA3gI_4hYcpUHVBAaaJopxj0UNtOe6Do0uc2QcZ04FUXypCJVAqRKHKkS6PNq02deBeb4Z-uOpeampQ2q7R7MFh-TmkcTI212wxxUTq4pyIBYx3CXeR5pZkigPHTUrIWkWahJFANKIpIx4qEXm2rgUUsmVZrZGtrImEsAciHz0ONq6WxGQmRABOA4D8mtRbU11O2aspi6OOChTRgUxOTp__i4Z-h2ZDnBRbU8Qgerxdo8B7y1SltoX0xECx12TocXly1ntWg5xoLrZefDL0V2LFA
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFLbGkIAbxD-BAUaCKxQ1iX_iXCBUNqp2XSukdah3nuM4NNKWhrVl2kvwKNzwHjwTx07SUYR2t6tYsR1ZOcfnfMc-Pwi9MYrnAJRDP9QEDJTIaF-pnPq5FoFSkcqMseeQozHvH9H9KZtuoZ9tLIx1q2xlohPU2VzbM_JOlIA2IoIx8qH65tuqUfZ2tS2hUbPF0Fycg8m2eD_YA_q-jaLep8lu32-qCviaJvHSJ4mKVZQykkKLgvbiWmSGuVUZkapM0VilALTTWOlcaxanTEeZyGxIKEs5ge_eQDdB8QbW2IunlwYeBWOrDcwRvLMAXQpiCLSidaCEFt9Qfq5GwP-A7b_-mX8pvN49dLdBqrhbs9Z9tGXKB-jWqLmLf4h-DMpZkRb2kh6D2DQVtPDuHo1xWrhQGbyc4wrA-anCk8PPIV6sKud1axZ4PPTtjQEe9Mb-71-4qtPOAovg74XCNtbCnhTbT8wM3u8OO4eT7oRgWz75XF3gOrYS9wdfcOtMVj5CR9dCh8dou5yX5inCgDnBigOgCPATZFAiuMoDGhMaaJopxj0Utr9d6ib1ua3AcSKdCSS4rEklgVTSkUrCnHfrOVWd-OPK0R8tNdcjbdJu92J-9lU2MkAaYasn5mDSck1BxyQ6gafI80gzQwLloZ2WF2QjSRbyku899HrdDTLAkkmVZr6CMSLhAoBiyDz0pGad9UqICEgMONFDYoOpNpa62VMWM5dnPLQFiYKEPLt6Xa_Q7f5kdCAPBuPhc3QnsvzucmPuoO3l2cq8ANS2TF-6rYLR8XXvzT-OyFa-
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibitory+receptor+CD47+binding+to+plasma+TSP1+suppresses+NK-cell+IFN-%CE%B3+production+via+activating+the+JAK%2FSTAT3+pathway+during+HIV+infection&rft.jtitle=Journal+of+translational+medicine&rft.au=Bin+Lang&rft.au=Meiting+Wang&rft.au=Zining+Zhang&rft.au=Yajing+Fu&rft.date=2023-11-30&rft.pub=BMC&rft.eissn=1479-5876&rft.volume=21&rft.issue=1&rft.spage=1&rft.epage=13&rft_id=info:doi/10.1186%2Fs12967-023-04667-6&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_e89369f1406c41119c9c418ff2c5e30a
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon